Literature DB >> 15056516

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.

Todd P Gilmer1, Christian R Dolder, Jonathan P Lacro, David P Folsom, Laurie Lindamer, Piedad Garcia, Dilip V Jeste.   

Abstract

OBJECTIVE: The authors' goal was to evaluate the relationship between adherence to treatment with antipsychotic medication and health expenditures. A secondary objective was to identify risk factors predictive of nonadherence.
METHOD: Data included Medicaid eligibility and claims data from 1998 to 2000 for San Diego County, Calif. Pharmacy records were used to assess adherence to treatment with antipsychotic medication according to the cumulative possession ratio (the number of days medications were available for consumption divided by the number of days subjects were eligible for Medi-Cal). Regression models were used to examine risk factors, hospitalizations, and costs associated with nonadherence, partial adherence, adherence, and excess fills of antipsychotic medication.
RESULTS: Forty-one percent of Medicaid beneficiaries with schizophrenia were found to be adherent to treatment with their antipsychotic medications: 24% were nonadherent, 16% were partially adherent, and 19% were excess fillers. Rates of psychiatric hospitalization were lower for those who were adherent (14%) than for those who were nonadherent (35%), partially adherent (24%), or had excess fills (25%). Rates of medical hospitalization were lower for those who were adherent (7%) than for those who were nonadherent (13%) or had excess fills (12%). Those who were adherent had significantly lower hospital costs than the other groups; pharmacy costs were higher among those who were adherent than among those who were nonadherent or partially adherent and were highest for excess fillers. Total costs for excess fillers (14,044 US dollars) were substantially higher than total costs for any other group.
CONCLUSIONS: Despite the widespread use of atypical antipsychotic medications, alarmingly high rates of both underuse and excessive filling of antipsychotic prescriptions were found in Medicaid beneficiaries with schizophrenia. The high rates of antipsychotic nonadherence and associated negative consequences suggest interventions on multiple levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056516     DOI: 10.1176/appi.ajp.161.4.692

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  170 in total

1.  How patient cost-sharing trends affect adherence and outcomes: a literature review.

Authors:  Michael T Eaddy; Christopher L Cook; Ken O'Day; Steven P Burch; C Ron Cantrell
Journal:  P T       Date:  2012-01

2.  Family caregivers' monitoring of medication usage: a qualitative study of Mexican-origin families with serious mental illness.

Authors:  Jorge A Marquez; Jorge I Ramírez García
Journal:  Cult Med Psychiatry       Date:  2011-03

Review 3.  Modern antipsychotic drugs: a critical overview.

Authors:  David M Gardner; Ross J Baldessarini; Paul Waraich
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

4.  Planning Patient-Centered Health Homes for Medicaid Psychiatric Patients at Greatest Risk for Intensive Service Use.

Authors:  Joyce C West; Donald S Rae; Ramin Mojtabai; Farifteh F Duffy; Janet Kuramoto; Eve Moscicki; William E Narrow
Journal:  Community Ment Health J       Date:  2015-02-10

5.  Adherence to antipsychotics among Latinos and Asians with schizophrenia and limited English proficiency.

Authors:  Todd P Gilmer; Victoria D Ojeda; Concepcion Barrio; Dahlia Fuentes; Piedad Garcia; Nicole M Lanouette; Kelly C Lee
Journal:  Psychiatr Serv       Date:  2009-02       Impact factor: 3.084

Review 6.  Psychotropic medication nonadherence among United States Latinos: a comprehensive literature review.

Authors:  Nicole M Lanouette; David P Folsom; Andres Sciolla; Dilip V Jeste
Journal:  Psychiatr Serv       Date:  2009-02       Impact factor: 3.084

7.  Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.

Authors:  Martha Sajatovic; Jennifer Levin; Luis F Ramirez; David Y Hahn; Curtis Tatsuoka; Christopher S Bialko; Kristin A Cassidy; Edna Fuentes-Casiano; Tiffany D Williams
Journal:  J Clin Psychiatry       Date:  2013-12       Impact factor: 4.384

8.  Families and medication use and adherence among Latinos with schizophrenia.

Authors:  Mercedes Hernandez; Concepción Barrio
Journal:  J Ment Health       Date:  2016-10-01

9.  A Medicaid and commercial insured claims-based study to estimate improved antipsychotic medication adherence among patients with schizophrenia.

Authors:  Bruce Pyenson; Sara Goldberg; Kosuke Iwasaki; Victoria Boyarsky; Riad Dirani
Journal:  J Behav Health Serv Res       Date:  2013-04       Impact factor: 1.505

10.  Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.

Authors:  Simon Frey; Roland Linder; Georg Juckel; Tom Stargardt
Journal:  Eur J Health Econ       Date:  2013-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.